{
  "lastUpdated": "2026-07-06",
  "semaglutide": {
    "STEP_1": {
      "mean_weight_loss_pct": 14.9,
      "duration_weeks": 68,
      "dose_mg": 2.4
    },
    "STEP_5": {
      "mean_weight_loss_pct": 15.2,
      "duration_years": 2
    },
    "SELECT": {
      "mace_reduction_pct": 20,
      "hazard_ratio": 0.8,
      "n": 17604,
      "note": "Cardiovascular event reduction, no diabetes required"
    },
    "titration_mg": [
      0.25,
      0.5,
      1.0,
      1.7,
      2.4
    ],
    "regain_note": "STEP 1 extension: ~two-thirds of lost weight returned within a year of stopping"
  },
  "tirzepatide": {
    "SURMOUNT_1": {
      "5mg_pct": 15.0,
      "10mg_pct": 19.5,
      "15mg_pct": 20.9,
      "placebo_pct": 3.1,
      "duration_weeks": 72
    },
    "SURMOUNT_5": {
      "tirzepatide_pct": 20.2,
      "semaglutide_pct": 13.7,
      "note": "Head-to-head, tirzepatide superior for weight loss"
    },
    "SURMOUNT_4": {
      "note": "Withdrawal led to substantial regain; continuation preserved loss"
    },
    "SURMOUNT_OSA": {
      "note": "First drug FDA-approved for obstructive sleep apnea"
    },
    "SURPASS": {
      "note": "Mounjaro diabetes program; HbA1c reductions often 2%+ points"
    },
    "titration_mg": [
      2.5,
      5,
      7.5,
      10,
      12.5,
      15
    ]
  },
  "boxed_warning": "Thyroid C-cell tumors; contraindicated with personal/family history of medullary thyroid carcinoma or MEN2"
}